Substituted pyrimidinone compound as well as preparation method and application thereof
By preparing substituted pyrimidinone compounds as PDE1 inhibitors, the problem of insufficient types of PDE1 inhibitors in the existing technology has been solved, and effective treatment of diseases such as pulmonary hypertension and idiopathic pulmonary fibrosis has been achieved.
Patent Information
- Application Number
- CN202510656403.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-21
- Publication Date
- 2026-01-02
AI Technical Summary
The current lack of PDE1 inhibitors limits treatment options for diseases such as pulmonary hypertension and idiopathic pulmonary fibrosis, and there is an urgent need for more types of PDE1 inhibitors to broaden the range of drug choices.
A substituted pyrimidinone compound and its pharmaceutically acceptable salt are provided, which are prepared as PDE1 inhibitors for the treatment of related diseases via a specific synthetic route.
The substituted pyrimidinone compounds exhibit good PDE1 inhibitory activity, have important medicinal value and broad application prospects, and are suitable for large-scale industrial production.
Smart Images

Figure CN121248634A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the technical field of medicine, more particularly, to a substituted pyrimidinone compound and a preparation method and application thereof.
[0002] Phosphodiesterases (PDEs) are an important superfamily of enzymes in the body, responsible for hydrolyzing intracellular second messenger molecules such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). By degrading these messenger molecules, PDEs can effectively terminate the biochemical signaling processes mediated by cAMP and cGMP. Studies have shown that cAMP and cGMP play a crucial role in the regulation of cell function, as second messengers of various biological signals such as neurotransmitters, hormones, light signals, and odors, widely affecting target organs within cells. The concentration regulation of cAMP and cGMP in cells mainly depends on the dynamic balance between the synthesis of nucleotide cyclase and the hydrolysis of PDEs.
[0003] PDEs are widely distributed in the body, and based on their protein sequence similarity, enzyme kinetic characteristics, regulatory mechanisms, cellular tissue distribution, and pharmacological properties, PDEs are divided into 11 different isozyme families (PDE1 to PDE11). Among them, PDE1 is identified as a calmodulin-dependent phosphodiesterase (CaM-PDE), whose activity is regulated by Ca 2+ and calmodulin, involved in the interaction of calcium signals and cyclic nucleotide signals. Studies have found that the signaling pathways regulated by PDE1 are closely related to the function of the central nervous system, and may play a role in pathological conditions such as mental illness, movement disorders, cognitive dysfunction, and Alzheimer's disease. In addition, PDE1 is also related to cardiac dysfunction, and may play a regulatory role in heart failure, cardiac remodeling, and dysfunction. Further studies have shown that PDE1 is also related to various physiological and pathological processes such as lung, kidney, hematology, gastrointestinal tract, liver, fertility, cancer, and metabolic disorders. Therefore, PDE1 inhibitors have shown important application potential in the field of disease treatment.
[0004] Currently, some PDE1 inhibitors have been developed as drugs for treating pulmonary arterial hypertension (PAH). However, the research and development of PDE1 inhibitors are still insufficient, and more types of PDE1 inhibitors are needed to broaden the selection range of drugs for research and clinical application. Further exploration in this field will help to promote the development of new treatment strategies and provide more possibilities for the management of related diseases. SUMMARY
[0005] In view of the above technical problems, the present application aims to provide a substituted pyrimidinone compound or a pharmaceutically acceptable salt thereof. The substituted pyrimidinone compound or the pharmaceutically acceptable salt thereof provided by the present application exhibits good inhibitory effect on phosphodiesterase type 1 (PDE1), can be used as a PDE1 inhibitor, and can be prepared into a drug for treating diseases such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis, and has important medicinal value and broad application prospect.
[0006] Another object of the present application is to provide a preparation method of the substituted pyrimidinone compound or the pharmaceutically acceptable salt thereof.
[0007] Still another object of the present application is to provide an application of the substituted pyrimidinone compound or the pharmaceutically acceptable salt thereof in preparing a phosphodiesterase inhibitor.
[0008] Still another object of the present application is to provide an application of the substituted pyrimidinone compound or the pharmaceutically acceptable salt thereof in preparing a drug for treating a phosphodiesterase related disease.
[0009] The above object of the present application is achieved by the following scheme:
[0010] The present application provides a substituted pyrimidinone compound or a pharmaceutically acceptable salt thereof, wherein the structure of the substituted pyrimidinone compound is shown in formula (I) or formula (II):
[0011]
[0012] R1 is C 1~8 alkyl, halophenyl, C 3~8 cycloalkyl or C 1~8 alkoxyphenyl;
[0013] R2 is hydrogen, halobenzyl, benzyl, phenyl;
[0014] R3 is C 1~8 alkyl; wherein C 1~8 alkyl is unsubstituted or substituted with one or more substituents selected from C 3~8 heterocyclyl and phenyl, C 3~8 cycloalkyl; wherein C 3~8 heterocyclyl in the heterocyclyl and phenyl is unsubstituted or substituted with one or more C 3~8 alkyl substituents; 1~8
[0015] R4 and R5 are each independently selected from hydrogen, halogen, C 1~6 alkoxy, C 1~6 haloalkoxy, C 1~8 alkyl, C1~8 haloalkyl;
[0016] X is selected from a carbon atom or a heteroatom, and wherein at least one is a heteroatom;
[0017] R6is hydrogen, C 1~8 alkyl;
[0018] R7is phenyl, halo-phenyl.
[0019] In particular, the heteroatom can be a nitrogen atom, an oxygen atom, a sulfur atom.
[0020] Preferably, R1is C 1~4 alkyl, halo-phenyl, C 3~6 cycloalkyl or C 1~4 alkoxy-phenyl;
[0021] R2is hydrogen, chloro-benzyl;
[0022] R3is C 1~4 alkyl; wherein C 1~4 alkyl is unsubstituted or substituted by one or more substituents selected from C 4~6 heteroaryloxy and phenyl, C 3~6 cycloalkyl; wherein C 4~6 heteroaryloxy in C 4~6 heteroaryl is unsubstituted or substituted by one or more C 1~4 alkyl substituents;
[0023] R4, R5are each independently selected from hydrogen, halogen, C 1~3 alkoxy, C 1~3 haloalkoxy, C 1~4 alkyl, C 1~4 haloalkyl;
[0024] X is selected from a carbon atom or a nitrogen atom, and wherein at least one is a nitrogen atom;
[0025] R6is hydrogen, C 1~4 alkyl;
[0026] R7is phenyl, halo-phenyl.
[0027] Preferably, R1is isobutyl, C 1~4 alkoxy-phenyl;
[0028] R2is hydrogen;
[0029] R3is C 1~3 alkyl, C 4~6 heteroaryloxy and benzyl; wherein C 1~3 alkyl is unsubstituted or substituted by one or more substituents selected from C3~6 Cycloalkyl substituents; wherein, C 4~6 C in heterocyclic benzyl group 4~6 Heterocyclic groups that are unsubstituted or via one or more C groups 1~3 Alkyl substituents;
[0030] R4 and R5 are each independently selected from hydrogen, halogens, and C. 1~3 Halogenated alkoxy groups, C 1~4 Alkyl, C 1~4 Halogenated alkyl groups;
[0031] X is selected from carbon atoms or nitrogen atoms, and at least one of them is a nitrogen atom;
[0032] R6 is hydrogen, C 1~4 alkyl;
[0033] R7 represents phenyl or fluorophenyl.
[0034] Preferably, R1 is isobutyl;
[0035] R2 is hydrogen;
[0036] R3 is
[0037] R4 and R5 are each independently selected from hydrogen, chlorine, fluorine, and C. 1~4 Alkyl, C 1~3 Halogenated alkoxy groups, C 1~4 Halogenated alkyl groups;
[0038] X is selected from carbon or nitrogen atoms, and at least one of them is a nitrogen atom.
[0039] Preferably, the substituted pyrimidinone compound or a pharmaceutically acceptable salt thereof is selected from any of the following structures:
[0040]
[0041] Furthermore, the present invention provides a method for preparing a substituted pyrimidinone compound or a pharmaceutically acceptable salt thereof, comprising the following steps:
[0042] S1. Compound C is prepared by mixing isothiocyanate (A), cyanoacetamide (B) and elemental sulfur under alkaline conditions;
[0043] S2. Compound C and dimethyl sulfate are mixed and heated under reflux to react. Then, carboxylic acid ester, water, and a reducing agent are added and heated under reflux to react to obtain compound D.
[0044] S3. Under alkaline conditions, compound C or compound D is mixed with a solution containing carbon disulfide and heated under reflux to react and yield compound I or compound E.
[0045] S4. Compound I or compound E reacts with compound F under alkaline condition to obtain compound G or compound J;
[0046] S5. Compound G or compound J reacts with compound H under alkaline condition to obtain compound (I) or compound (II);
[0047] The synthetic route is as follows:
[0048]
[0049] More specifically, in some specific embodiments, the preparation method of the substituted pyrimidinone compound comprises the following specific steps:
[0050] S1. Cyanacetamide (B) is mixed with elemental sulfur in an organic solvent, and then isothiocyanate (A) is added dropwise after adding a basic reagent, and is reacted at 40-50°C for 1-5h, and then the filter residue is filtered and washed to obtain compound C;
[0051] S2. Compound C and dimethyl sulfate are mixed in an organic solvent, and then after being heated to reflux overnight, it is cooled to room temperature, and then ethyl acetate, water and a reducing reagent are added and heated to reflux to obtain compound D;
[0052] S3. Carbon disulfide is added to an organic solution containing a basic reagent, a small amount of water is added, and then compound C or compound D is added, and after being sealed, it is heated to reflux and reacted overnight, and then it is cooled to room temperature to crystallize, and then the filter residue is filtered and washed to obtain compound I or compound E;
[0053] S4. Compound I or compound E is mixed with compound F in an organic solvent, and then a basic reagent is added, and then it is reacted at room temperature for 1-3h to obtain compound G or compound J;
[0054] S5. Compound G or compound J is mixed with compound H in an organic solvent, and then a basic reagent is added, and then it is reacted at room temperature to obtain compound (I) or compound (II);
[0055] Preferably, the organic solvent in the reaction of steps S1 and S3 is preferably anhydrous ethanol; and the basic reagent in step S1 is preferably triethylamine.
[0056] Preferably, in step S1, the molar ratio of cyanacetamide to isothiocyanate is 1:1.2-1.5, and the molar ratio of cyanacetamide to basic reagent is 1:1.5-2.5.
[0057] Preferably, in step S2, the organic solvent is preferably acetonitrile; the heating reflux temperature is 95-105°C; and the reducing reagent is at least one of sodium sulfite and sodium metabisulfite.
[0058] Preferably, the molar ratio of compound C to dimethyl sulfate in step S2 is 1:1.5-2.
[0059] Preferably, the reaction in step S3 is carried out in a cylindrical glass sealing tube and the solvent is added to the sealing tube solvent 1 / 2; preferably, the heating reflux temperature is 95-105℃.
[0060] Preferably, the molar ratio of compound C or compound D to carbon disulfide in step S3 is 1:8-12.
[0061] Preferably, the organic solvent in step S4 is preferably at least one of anhydrous ethanol, methanol, acetonitrile, acetone.
[0062] Preferably, the molar ratio of compound E or compound I to compound F in step S4 is 1:0.8-1.2.
[0063] Preferably, the organic solvent in steps S4, S5 is preferably at least one of anhydrous ethanol, methanol, acetonitrile, acetone; the basic reagent in steps S3, S4, S5 is preferably at least one of potassium carbonate, potassium hydroxide, sodium hydroxide; the molar ratio of compound to basic reagent is 1:1.5-2.5.
[0064] Preferably, the molar ratio of compound G or compound J to compound H in step S5 is 1:1-1.5.
[0065] Further, the present application claims the use of the substituted pyrimidinone compound or a pharmaceutically acceptable salt thereof in the preparation of a phosphodiesterase inhibitor.
[0066] Further, the present application claims the use of the substituted pyrimidinone compound or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating a phosphodiesterase-related disease.
[0067] Preferably, the phosphodiesterase is phosphodiesterase type 1.
[0068] Preferably, the phosphodiesterase-related disease is one or more of pulmonary arterial hypertension, idiopathic pulmonary fibrosis, pneumonia, enteritis, vascular dementia, or Alzheimer's disease.
[0069] Compared with the prior art, the present application has the following beneficial effects:
[0070] The application provides a substituted pyrimidinone compound, which shows good inhibition on phosphodiesterase type 1 (PDE1), can be applied as a PDE1 inhibitor, can be prepared into a medicine for treating diseases such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis, and has important medicinal value and wide application prospect. The substituted pyrimidinone compound has a novel structure, and its preparation method is simple, and is suitable for large-scale industrial production and application. DETAILED DESCRIPTION
[0071] The application will be further described in detail in combination with specific examples, and the examples are only used for explaining the application, and are not used for limiting the range of the application. In the following examples, the test methods are conventional methods, and the materials and reagents used are commercially available reagents and materials, unless otherwise specified.
[0072] Preparation of compound 1 and compound 2 in example 1
[0073] The synthesis route of the compound 1 and the compound 2 is as follows:
[0074]
[0075] Specifically includes the following steps:
[0076] S1, cyanacetamide (672 mg, 8 mmol), sulfur (256 mg, 8 mmol) are weighed in a single-necked flask, a suspension is formed after adding anhydrous ethanol (8 mL, 137 mmol), then triethylamine (2228 μL, 16 mmol) is added and slowly dropped into 3-methoxy isothiocyanate (1.5 mL, 10.7 mmol), the obtained suspension system is reacted at 45℃ for 1 h, it is observed that the system is dissolved to be clear at 0-30 min, and a large amount of yellow precipitate is generated at 30 min-1 h, at this time, the reaction is completed by TLC monitoring, filtration, and the filter residue is washed with anhydrous ethanol for multiple times, and dried to obtain a light yellow solid, which is compound 1a (2.024 g), and the yield is 90%. The reaction equation is as follows:
[0077]
[0078] S2, Compound 1a (800 mg, 2.84 mmol) was dissolved in acetonitrile (10 mL, 191 mmol), dimethyl sulfate (404 μL, 4.27 mmol) was added, and the reaction was carried out at 100°C overnight after cooling to room temperature. Ethyl acetate (5 mL), water (10 mL), and anhydrous sodium sulfite (716 mg, 5.68 mmol) were added, and the reaction was heated to reflux at 100°C for 30 min after cooling to room temperature. TLC monitoring showed that the reaction was complete in the organic phase, and the solution system was clearly separated. The solution was transferred to a separatory funnel, the organic phase was collected, and ethyl acetate (3 mL x 3) was added to extract the aqueous phase. The organic phase was combined, washed with saturated sodium chloride solution (10 mL x 3), dried over anhydrous sodium sulfate, and purified by column chromatography (dichloromethane:methanol = 50:1). The yellow solid obtained by rotary evaporation was compound 1b (573 mg), with a yield of 76%. The reaction equation is:
[0079]
[0080] S3, Potassium hydroxide (242 mg, 4.32 mmol) was weighed into a 75 mL cylindrical glass sealed tube, and anhydrous ethanol (20 mL, 342 mmol) was added. After stirring at room temperature until complete dissolution, carbon disulfide (1.3 mL, 21.6 mmol) was added, the sealed tube was closed, and stirring was carried out at room temperature for 30 min. Compound 1b (573 mg, 2.16 mmol) was weighed into the sealed tube, and anhydrous ethanol (10 mL, 171 mmol) and water (1.2 mL, 66.7 mmol) were added. The sealed tube was closed, and the reaction was carried out at 100°C overnight. After cooling to room temperature, a solid was precipitated, the sealed tube was opened, and TLC monitoring showed that the reaction was complete. The system was placed in a fume hood and stirred for 2 h to volatilize carbon disulfide and its toxic reaction products. The solution was transferred to a 250 mL single-necked flask with water, the ethanol was removed by rotary evaporation, and the solution became clear. A large amount of solid was precipitated by slowly adding 2M aqueous hydrochloric acid solution to adjust the pH to 5-6. The filtrate was washed with water several times, and dried to obtain a yellow solid, which was compound 1c (447 mg), with a yield of 67%. The reaction equation is:
[0081]
[0082] S4, Compound 1c (80 mg, 0.26 mmol), 4-chlorobenzyl bromide (64 mg, 0.26 mmol), potassium carbonate (68 mg, 0.52 mmol) were weighed into a 25 mL single-necked flask, and then ethanol (10 mL, 171 mmol) was added to form a suspension, which was stirred at room temperature for 1.5 h. After the reaction was completed as monitored by TLC, the product was purified by column chromatography (dichloromethane:methanol = 30:1) to obtain Compound 1 (81 mg) as a yellow solid, with a yield of 72%. The reaction equation is as follows:
[0083]
[0084] S5, Compound 1 (60 mg, 0.134 mmol), potassium carbonate (37 mg, 0.268 mmol) were weighed into a 25 mL single-necked flask, and then acetone (10 mL, 136 mmol) was added to form a suspension, and then 4-fluorobenzyl bromide (17 μL, 0.134 mmol) was added dropwise. The reaction was stirred at room temperature overnight. After the reaction was completed as monitored by TLC, the product was purified by column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain Compound 2 (30 mg) as a white solid, with a yield of 42%. The reaction equation is as follows:
[0085]
[0086] Substituted pyrimidinone compounds 1-38 were prepared according to the preparation method of Example 1 and the above synthesis route.
[0087] Substituted pyrimidinone compounds 39-44 were prepared according to the preparation method of Example 1 and the above synthesis route, except that the operation of step S2 was not performed, and the operation of step S3 was directly performed.
[0088] The specific structures of the substituted pyrimidinone compounds 1-44 are as follows:
[0089]
[0090]
[0091] The nuclear magnetic resonance data of the substituted pyrimidinone compounds 1-44 are shown in Table 1.
[0092] Table 1 Nuclear magnetic resonance data of substituted pyrimidinone compounds 1-44
[0093]
[0094]
[0095]
[0096]
[0097]
[0098] Example 2: Activity test of substituted pyrimidinone compounds 1-44
[0099] Using the substituted pyrimidinone compounds 1-44 prepared in Example 1 above as subjects, their inhibitory activity against phosphodiesterase type 1 was determined at a concentration of 100 nM. The inhibition rate of the compounds against phosphodiesterase type 1 under these two concentration conditions refers to the inhibition rate of phosphodiesterase type 1 obtained at a concentration of 100 nM. The test used radioisotope-labeled cyclic guanosine monophosphate (cGMP). 3 Using H-cGMP as a substrate, the inhibitory activity of PDE1C inhibitors was assessed by radioactive monitoring of the amount of hydrolysis products generated. The specific experimental procedure is as follows:
[0100] (1) Reagent preparation:
[0101] Assay Buffer: Contains 50 mM Tris-HCl (pH 7.5), 0.5 mM dithiothreitol (DTT), and 4 mM NCl2 to maintain enzyme activity and reaction stability. Substrate Solution: [The following appears to be a separate, unrelated section:] ... 3 The H-cGMP stock solution was diluted 50-fold with deionized water to prepare a stock solution, which was then diluted with Assay Buffer to the working concentration (substrate radioactivity count range of 17,000-23,000 cpm for a 58 μL reaction system). Inhibitor stock solution: The analyte was dissolved in DMSO to prepare a 100 mM high-concentration stock solution, followed by serial dilutions (7-9 concentration gradients) to determine the IC50. 50 value.
[0102] (2) Protein concentration optimization:
[0103] After purification, PDE1C protein was revived from -80°C and diluted to different concentrations at 0°C with Assay Buffer. A blank control group (Assay Buffer only) and experimental groups (containing different protein concentrations) were set up, with each group consisting of a 100 μL reaction mixture (containing 58 μL substrate solution and 2 μL DMSO). After incubation at room temperature for 15 minutes, the reaction was terminated by adding 0.2 M zinc sulfate and 0.2 M barium hydroxide solution. Unhydrolyzed substrate was separated by high-speed centrifugation. The supernatant was bound to scintillation fluid, and the radioactivity intensity was measured using a liquid scintillation counter to calculate the hydrolysis rate at each protein concentration (45%-75% was the preferred concentration).
[0104] (3) Inhibitory activity detection:
[0105] In the centrifuge tube, 58 μL of substrate solution was added, and 2 μL of DMSO, DMSO solution of the test compound was added to the blank group and the test group, respectively. Then, 40 μL of buffer was added to the blank group, and 40 μL of protein solution with a hydrolysis rate of 45%-75% was added to the experimental group, and then mixed and reacted at room temperature for 15 minutes. The subsequent operation was consistent with step one of the protein concentration optimization.
[0106] (4) Data analysis:
[0107] The compound concentration (molar concentration) and the corresponding inhibition rate data were imported into GraphPad Prism 8.0.1 software, and the nonlinear regression model "log(inhibitor) vs. response" was used to fit the dose-effect curve, and the IC 50 value was calculated.
[0108] The half-inhibitory concentration (IC 50 ) of the substituted pyrimidinone compounds 1-44 prepared in Example 1 above on phosphodiesterase type 1 was determined. The IC 50 value below 50000 nM indicates that the compound exhibits inhibition of PDE1. The results measured are shown in Table 2.
[0109] Table 2 Inhibition of phosphodiesterase type 1 by substituted pyrimidinone compounds 1-44
[0110]
[0111]
[0112] In Table 2, "nd" means "not detected"; * indicates the inhibition rate of phosphodiesterase type 1 obtained by the compound at a concentration of 1000 nM
[0113] As can be seen from Table 2, most of the compounds exhibit certain inhibition of phosphodiesterase type 1, among which compounds 1, 3, 7-9, 13, 16, 18, 20, 22, 24-27, 30-31, 36, 38-39 exhibit particularly obvious inhibition of phosphodiesterase type 1, and the IC 50 values of all of them are less than 300 nM. In particular, compounds 7, 9, 13, 16, 20, 22, 24, 26, 30, the IC 50 values of all of them are less than 30 nM, exhibiting significant inhibition of phosphodiesterase type 1.
[0114] The above examples are only used to illustrate the technical solutions of the present application and not to limit the protection scope of the present application. Based on the above description and ideas, those skilled in the art can make other different forms of changes or modifications, which do not need to be or cannot be exhausted here. Any modification, equivalent replacement and improvement made within the spirit and principle of the present application shall be included in the protection scope of the claims of the present application.
Claims
1. A substituted pyrimidinone compound or a pharmaceutically acceptable salt thereof, characterized in that, The structures of the substituted pyrimidinone compounds are shown in formula (I) or formula (II): Where R1 is C 1~8 Alkyl, halophenyl, C 3~8 cycloalkyl or C 1~8 Alkoxyphenyl; R2 is hydrogen, halobenzyl, benzyl, or phenyl; R3 is C 1~8 Alkyl; wherein, C 1~8 Alkyl groups are unsubstituted or derived from one or more C16 groups. 3~8 Heterocyclic phenyl group, C 3~8 Cycloalkyl substituents; wherein, C 3~8 C in heterocyclic phenyl 3~8 Heterocyclic groups are unsubstituted or via one or more C groups 1~8 Alkyl substituents; R4 and R5 are each independently selected from hydrogen, halogens, and C. 1~6 Alkoxy, C 1~6 Halogenated alkoxy groups, C 1~8 Alkyl, C 1~8 Halogenated alkyl groups; X is selected from carbon atoms or heteroatoms, and at least one of them is a heteroatom; R6 is hydrogen, C 1~8 alkyl; R7 represents phenyl or halophenyl.
2. The substituted pyrimidinone compound or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that, R1 is C 1~4 Alkyl, halophenyl, C 3~6 cycloalkyl or C 1~4 Alkoxyphenyl; R2 is hydrogen or chlorobenzyl; R3 is C 1~4 Alkyl; wherein, C 1~4 Alkyl groups are unsubstituted or derived from one or more C16 groups. 4~6 Heterocyclic phenyl group, C 3~6 Cycloalkyl substituents; wherein, C 4~6 C in heterocyclic phenyl 4~6 Heterocyclic groups are unsubstituted or via one or more C groups 1~4 Alkyl substituents; R4 and R5 are each independently selected from hydrogen, halogens, and C. 1~3 Alkoxy, C 1~3 Halogenated alkoxy groups, C 1~4 Alkyl, C 1~4 Halogenated alkyl groups; X is selected from carbon atoms or nitrogen atoms, and at least one of them is a nitrogen atom; R6 is hydrogen, C 1~4 alkyl; R7 represents phenyl or halophenyl.
3. The substituted pyrimidinone compound or a pharmaceutically acceptable salt thereof according to claim 2, characterized in that, R1 is isobutyl, C 1~4 Alkoxyphenyl; R2 is hydrogen; R3 is C 1~3 Alkyl, C 4~6 Heterocyclic benzobenzyl; wherein, C 1~3 Alkyl groups are unsubstituted or derived from one or more C16 groups. 3~6 Cycloalkyl substituents; wherein, C 4~6 C in heterocyclic benzyl group 4~6 Heterocyclic groups are unsubstituted or via one or more C groups 1~3 Alkyl substituents; R4 and R5 are each independently selected from hydrogen, halogens, and C. 1~3 Halogenated alkoxy groups, C 1~4 Alkyl, C 1~4 Halogenated alkyl groups; X is selected from carbon atoms or nitrogen atoms, and at least one of them is a nitrogen atom; R6 is hydrogen, C 1~4 alkyl; R7 represents phenyl or fluorophenyl.
4. The substituted pyrimidinone compound according to claim 3, or a pharmaceutically acceptable salt thereof, characterized in that, R1 is isobutyl; R2 is hydrogen; R3 is R4 and R5 are each independently selected from hydrogen, chlorine, fluorine, and C. 1~4 Alkyl, C 1~3 Halogenated alkoxy groups, C 1~4 Halogenated alkyl groups; X is selected from carbon or nitrogen atoms, and at least one of them is a nitrogen atom.
5. The substituted pyrimidinone compound according to claim 4, or a pharmaceutically acceptable salt thereof, characterized in that, Selected from any of the following structures:
6. A method for preparing the substituted pyrimidinone compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, characterized in that, Includes the following steps: S1. Compound C is prepared by mixing isothiocyanate (A), cyanoacetamide (B) and elemental sulfur under alkaline conditions; S2. Compound C and dimethyl sulfate are mixed and heated under reflux to react. Then, carboxylic acid ester, water, and a reducing agent are added and heated under reflux to react to obtain compound D. S3. Under alkaline conditions, compound C or compound D is mixed with a solution containing carbon disulfide and heated under reflux to react and yield compound I or compound E. S4. Under alkaline conditions, compound I or compound E reacts with compound F to give compound G or compound J; S5. Under alkaline conditions, compound G or compound J reacts with compound H to give compound (I) or compound (II); The synthesis route is as follows:
7. Use of the substituted pyrimidinone compound of any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof in the preparation of a phosphodiesterase inhibitor.
8. The use of the substituted pyrimidinone compound of any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating phosphodiesterase-related diseases.
9. The application according to claim 7 or 8, characterized in that, The phosphodiesterase is phosphodiesterase type 1.
10. The application according to claim 8, characterized in that, Phosphodiesterase-related diseases include one or more of the following: pulmonary hypertension, idiopathic pulmonary fibrosis, pneumonia, enteritis, vascular dementia, or Alzheimer's disease.
